Gensight Biologics Sa

GenSight Biologics Announces the Filing of its 2025 Universal Registration Document

GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026

GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®

GenSight Biologics Announces the Closing of its Nearly €1.7 Million Fundraising